A WHO regional journal report, written with Iraqi Ministry of Health and WHO staff, describing how medicines are approved, priced, bought, tested and monitored in Iraq, and naming budget shortfalls and shortages of essential medicines among the main problems.
Published as "Pharmaceutical regulations in Iraq: from medicine approval to postmarketing". The main source was the Iraq pharmaceutical country profile 2020, prepared by the Ministry of Health with WHO. The report describes the Directorate of Technical Affairs as the regulator, the National Committee for Drug Selection and the essential and comprehensive medicines lists, registration and fast-track registration, pricing rules, KIMADIA's public procurement, the National Centre for Drug Control and Research, the Iraqi Pharmacovigilance Centre and the separate regulation of medicines in the Kurdistan Region.
It is the clearest public description of the route a cancer medicine takes into Iraq and into public hospitals, written partly by the people who run that route.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/